about
Lifestyle risk factors associated with arm swelling among women with breast cancer.Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerWhich imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?Margin index: a useful tool for the breast surgeon?Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.Improving participation and quality of clinical research in a university-based general surgery residency program.Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age.A cost-utility analysis of the use of preoperative computed tomographic angiography in abdomen-based perforator flap breast reconstruction.A Cost-Utility Analysis Comparing the Sartorius versus the Rectus Femoris Flap in the Treatment of the Infected Vascular Groin Graft Wound.Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.Medical School Surgical Boot Camps: A Systematic Review.Identification of breast cancer margins using intraoperative near-infrared imaging.Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review.Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.Resident and Fellow Participation in Breast Surgery: An American College of Surgeons NSQIP Clinical Outcomes Analysis.Early Postoperative Outcomes in Breast Conservation Surgery Versus Simple Mastectomy with Implant Reconstruction: A NSQIP Analysis of 11,645 Patients.Early postoperative outcomes in lumpectomy versus simple mastectomy.Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancerUltrasound-guided lumpectomy for palpable breast cancers.Abstract 56. A Cost-utility Analysis Comparing Large Volume Displacement Oncoplastic Surgery to Mastectomy with Free Flap Reconstruction in the Treatment of Breast Cancer.Abstract 62: A Cost-utility Analysis Comparing Large Volume Displacement Oncoplastic Surgery To Mastectomy With Single Stage Implant Reconstruction In The Treatment Of Breast Cancer.Resource Usage Implementing the Surgical Resident Prep Curriculum at a Single Institution.Reconstruction patterns in a single institution cohort of women undergoing mastectomy for breast cancer.Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.Patient preference and timing for exercise in breast cancer care.Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancerMargin Index Is Not a Reliable Tool for Predicting Residual Disease after Breast-Conserving Surgery for DCISAbstract QS30War wounds of the pancreasOutcomes for patients who develop both breast and colorectal cancer
P50
Q34004915-61CD0565-B1EB-4A31-BF30-61696AA882AAQ35807188-2C8E60BC-8A5B-40ED-950C-45874FD23C46Q36640972-79AC2E08-A6C5-4611-9C90-ACF670442C0FQ36970943-B37BB160-110F-4EAA-BC31-3206FFCA85FAQ37482192-B6A0CB5F-03FA-428E-B071-D292D3F24C3DQ37779081-672F5110-5E1B-4C0B-8E38-3522AE8000F5Q38029521-F3C8E3D5-B1BC-49D9-9F5A-3B04BE5510C5Q38291717-DFB2E0CF-7BC7-4A5D-B4C9-449D47762858Q38367966-A549E23A-3A7B-46AF-B26B-D78E51BD0CA1Q38429498-59B957EE-4086-4E9E-9810-24359490956DQ38784581-6A605F07-7B46-4669-AD0F-6FE7B2BA2E5AQ38796801-108028D1-4D43-458D-A2CF-2AE4E0A00872Q38880977-1BEF898B-E1E6-4EFA-B96E-757106010B36Q39003439-E124B3ED-94E6-4361-A17A-ECC8DE6D4864Q40426503-73F6FF99-1BA9-43B9-B5A7-BF7255289F6AQ40537262-E08842BE-9903-4CA6-A390-1F59BC11AD52Q41085862-DC0FD53D-C512-4ACE-B798-E956CC848797Q41165020-7E9968D3-9ED7-46B0-9547-0C4D2C991018Q41716752-8D8D168E-4FBB-4121-99EE-FA813B7AB7BAQ44524766-1CBA195D-D32A-4BAC-9AEC-4D241845FF2BQ45967764-FB27598D-8D20-46A7-821E-C074C9F57EAEQ47171392-00368967-FB38-40A7-A3EA-2AB5C0007A0BQ47241724-5E543F1B-6654-4BFE-B410-CDF9C17827C9Q47283229-8A8F076F-D511-4F34-B220-5BBFC73BF3E1Q48011136-0DF5ABDC-3F85-4B92-99A8-3A5493665FB2Q50495928-DD46C217-FF20-40B9-AF41-23E343CA8A4BQ52909381-C1FCA966-FBB4-41C8-9BB8-BB771C09BD74Q57105081-53B5D874-81BE-4E44-9842-BE1BEBA7F0AAQ60369031-B2ABB0F5-28EF-4A53-867D-59D44023BD05Q64243048-45C626D8-EF6C-48D8-B4D3-0C53C0A4483CQ83649762-7CC57E52-6F1F-4AC8-A7C3-9D363A558BEEQ84437630-3F21CB75-ACB3-4AF0-8321-F6B605624EC2
P50
description
academic
@en
name
Carla S. Fisher
@en
Carla S. Fisher
@es
type
label
Carla S. Fisher
@en
Carla S. Fisher
@es
prefLabel
Carla S. Fisher
@en
Carla S. Fisher
@es